Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy. Review uri icon

Overview

abstract

  • The first 15 years of management of gastrointestinal stromal tumor (GIST) have led to 3 lines of therapy for metastatic disease: imatinib, sunitinib, and regorafenib. In the adjuvant setting, imatinib is usually given for 3 years postoperatively to patients with higher-risk primary tumors that are completely resected. In this review, issues regarding GIST adjuvant therapy are discussed. It is hoped this review will help the reader understand the present standard of care to improve upon it in years to come.

publication date

  • September 1, 2016

Research

keywords

  • Antineoplastic Agents
  • Chemotherapy, Adjuvant
  • Digestive System Surgical Procedures
  • Gastrointestinal Neoplasms
  • Gastrointestinal Stromal Tumors
  • Imatinib Mesylate
  • Neoadjuvant Therapy

Identity

Scopus Document Identifier

  • 84991257167

Digital Object Identifier (DOI)

  • 10.1016/j.gtc.2016.04.006

PubMed ID

  • 27546844

Additional Document Info

volume

  • 45

issue

  • 3